1. Home
  2. NAMS vs HURN Comparison

NAMS vs HURN Comparison

Compare NAMS & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • HURN
  • Stock Information
  • Founded
  • NAMS 2019
  • HURN 2002
  • Country
  • NAMS Netherlands
  • HURN United States
  • Employees
  • NAMS N/A
  • HURN N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • HURN Professional Services
  • Sector
  • NAMS Health Care
  • HURN Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • HURN Nasdaq
  • Market Cap
  • NAMS 3.1B
  • HURN 2.6B
  • IPO Year
  • NAMS N/A
  • HURN 2004
  • Fundamental
  • Price
  • NAMS $38.74
  • HURN $165.00
  • Analyst Decision
  • NAMS Strong Buy
  • HURN Strong Buy
  • Analyst Count
  • NAMS 10
  • HURN 4
  • Target Price
  • NAMS $43.70
  • HURN $175.25
  • AVG Volume (30 Days)
  • NAMS 1.3M
  • HURN 184.8K
  • Earning Date
  • NAMS 11-06-2025
  • HURN 10-28-2025
  • Dividend Yield
  • NAMS N/A
  • HURN N/A
  • EPS Growth
  • NAMS N/A
  • HURN 32.32
  • EPS
  • NAMS N/A
  • HURN 5.98
  • Revenue
  • NAMS $64,006,000.00
  • HURN $1,618,977,000.00
  • Revenue This Year
  • NAMS N/A
  • HURN $13.32
  • Revenue Next Year
  • NAMS N/A
  • HURN $8.31
  • P/E Ratio
  • NAMS N/A
  • HURN $27.65
  • Revenue Growth
  • NAMS 762.15
  • HURN 12.67
  • 52 Week Low
  • NAMS $14.06
  • HURN $108.22
  • 52 Week High
  • NAMS $41.47
  • HURN $174.26
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 66.43
  • HURN 69.39
  • Support Level
  • NAMS $35.50
  • HURN $150.49
  • Resistance Level
  • NAMS $39.03
  • HURN $174.26
  • Average True Range (ATR)
  • NAMS 2.30
  • HURN 4.62
  • MACD
  • NAMS -0.16
  • HURN 1.31
  • Stochastic Oscillator
  • NAMS 61.67
  • HURN 68.00

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

Share on Social Networks: